MAP2K7 and non-small cell lung carcinoma: Another MEK inhibitor, trametinib, was also evaluated alone or in combination with taxanes and revealed that combination with chemotherapy increased tolerability and clinical activity in both KRAS-mutant and KRAS-WT NSCLC patients [90].